↑Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran TA, Semple G, Thomsen W (May 2005). "Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists". The Journal of Pharmacology and Experimental Therapeutics313 (2): 831–9. PMID15677346. doi:10.1124/jpet.104.081711.Cite uses deprecated parameter |month= (help)
↑Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, Kramer B, Hsu D, Casper M, Thomsen B, Sekiguchi Y (September 2005). "Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1". Bioorganic & Medicinal Chemistry Letters15 (17): 3853–6. PMID16002290. doi:10.1016/j.bmcl.2005.05.121.Cite uses deprecated parameter |month= (help)
↑Chaki S, Yamaguchi J, Yamada H, Thomsen W, Tran TA, Semple G, Sekiguchi Y (2005). "ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety". CNS Drug Reviews11 (4): 341–52. PMID16614734. doi:10.1111/j.1527-3458.2005.tb00052.x.
